Autolus Therapeutics to Participate in Upcoming Investor Conferences in September
- Dr.
Christian Itin , chairman and chief executive officer, will present at theWells Fargo 2019 Healthcare Conference inBoston onWednesday, September 4 at3:00 p.m. ET and will host one-on-one meetings with attendees. A live webcast of the presentation will be available on the investor relations section of Autolus’ website at https://www.autolus.com. An archived replay will be available on the company’s website for a period of 90 days after the conference. - Dr. Itin will participate in a fireside chat at the
Morgan Stanley 17th Annual Global Healthcare Conference inNew York onMonday, September 9 at9:20 a.m. ET and will host one-on-one meetings with attendees. A live audio webcast of the fireside chat will be available on the investor relations section of Autolus’ website at https://www.autolus.com. An archived replay will be available on the company’s website for a period of 90 days after the conference. Andrew Oakley , chief financial officer, will present at theH.C. Wainwright 21st AnnualGlobal Investment Conference inNew York onTuesday, September 10 at2:10 p.m. ET and will host one-on-one meetings with attendees.
About
Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. For more information, go to: https://www.autolus.com.
Investor contact:
S.A. Noonan Communications
+1-212-966-3650
susan@sanoonan.com
Media contacts:
Vice President,
Autolus
+1-240-801-3850
s.taylor@autolus.com
JW Communications
+44 (0) 7818 430877
j.wilson@autolus.com
Source: Autolus Therapeutics plc